Table of Contents

2020 Month : March Volume : 9 Issue : 9 Page : 645-650

A Study to Detect Liver Enzyme Dysfunction among Patients on First Line Anti-Tubercular Drugs from RNTCP during the Course of Anti-TB Treatment.

Rupam Kumar T. A.1, Samim Khan2, Pronoy Sen3, Sourindranath Banerjee4

1Department of Chest Medicine, Burdwan Medical College and Hospital, Bardhaman, West Bengal, India. 2Department of Chest Medicine, Burdwan Medical College and Hospital, Bardhaman, West Bengal, India. 3Department of Chest Medicine, Burdwan Medical College and Hospital, Bardhaman, West Bengal, India. 4Department of Chest Medicine, Burdwan Medical College and Hospital, Bardhaman, West Bengal, India.

References :

1

Hershkovitz I, Donoghue HD, Minnikin DE, et al. Tuberculosis origin: The Neolithic scenario. Tuberculosis (Edinb) 2015;95(Suppl 1):S122-6.              

CrossRef | Google Scholar | PubMed
2

Sakula A. Robert Koch: centenary of the discovery of the tubercle bacillus, 1882. Thorax 1982;37(4):246-51.              

CrossRef | Google Scholar | PubMed
3

Global Tuberculosis Report 2018. WHO - executive summary. 2018: p. 17.

4

Revised National Tuberculosis Control Programme, National Strategic Plan for Tuberculosis Elimination -2017-2025: p. 5.           

5

Schaberg T, Rebhan K, Lode H. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. European Respiratory Journal 1996;9(10):2026-30.            

CrossRef | Google Scholar | PubMed
6

Kishore PV, Palaian S, Paudel R, et al. PR-drug induced hepatitis with anti-tubercular chemotherapy: challenges and difficulties in treatment. Kathmandu University Medical Journal (KUMJ) 2007;5(2):256-60.                       

Google Scholar | PubMed
7

Sharma SK, Balamurugan A, Saha PK, et al. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. American Journal of Respiratory and Critical Care Med 2002;166(7):916-9.      

CrossRef | Google Scholar | PubMed
8

Isa SE, Ebonyi AO, Shehu NY, et al. Antituberculosis drugs and hepatotoxicity among hospitalized patients in Jos, Nigeria. International Journal of Mycobacteriology 2016;5(1):21-6.                        

CrossRef | Google Scholar | PubMed
9

Sharma SK, Mohan A. Antituberculosis treatment-induced hepatotoxicity: from bench to bedside. Chap - 96. In: Gupta SB, edr, Medicine Update. Mumbai: The Association of Physicians of India 2005;15:479-84.

10

Ramappa V, Aithal GP. Hepatotoxicity related to anti-tuberculosis drugs: mechanisms and management. Journal of Clinical and Experimental Hepatology 2013;3(1):37-49.   

CrossRef | Google Scholar | PubMed
11

Chang KC, Leung CC, Yew WW, et al. Standard anti-tuberculosis treatment and hepatotoxicity: do dosing schedules matter? European Respiratory Journal 2007;29(2):347-51.                   

CrossRef | Google Scholar | PubMed
12

Yew WW, Leung CC. Antituberculosis drugs and hepatotoxicity. Respirology 2006;11(6):699-707.                   

CrossRef | Google Scholar | PubMed
13

Devarbhavi H, Dierkhising R, Kremers WK. et al. Single- center experience with drug-induced liver injury from India: causes, outcome, prognosis, and predictors of mortality. American Journal Gastroenterology 2010;105(11):2396-404.           

CrossRef | Google Scholar | PubMed
14

Ostapowicz G, Fontana RJ, Schiodt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002;137(12):947-54.     

CrossRef | Google Scholar | PubMed
15

Kumar R, Shalimar, Bhatia V, et al. Antituberculosis therapy induced acute liver failure: magnitude, profile, prognosis and predictors of outcome. Hepatology 2010;51(5):1665-74.               

CrossRef | Google Scholar | PubMed
16

Tostmann A, Boeree MJ, Aarnoutse RE, et al. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol 2008;23(2):192-202.      

CrossRef | Google Scholar | PubMed
17

Mitchell JR, Zimmerman HJ, Ishak KG, et al. Isoniazid liver injury: clinical spectrum, pathology and probable pathogenesis. Ann Intern Med 1976;84(2):181-92.          

CrossRef | Google Scholar | PubMed
18

Scharer L, Smith JP. Serum transaminase elevations and other hepatic abnormalities in patients receiving isoniazid. Ann Intern Med 1969;71(6):1113-20.    

CrossRef | Google Scholar | PubMed
19

Kopanoff DE, Snider DE Jr, Caras GJ. Isoniazid-related hepatitis: a U.S. Public Health Service Cooperative Surveillance Study. Am Rev Respir Dis 1978;117(6):991-1001.

CrossRef | Google Scholar | PubMed
20

International Union against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ 1982;60(4):555-64.       

CrossRef | Google Scholar | PubMed
21

Lacroix C, Tranvouez JL, Hoang PT, et al. Pharmacokinetics of pyrazinamide and its metabolites in patients with hepatic cirrhotic insufficiency. Arzneimittelforschung 1990;40(1):76-9.  

Google Scholar | PubMed
22

Singh J, Garg PK, Tandon RK. Hepatotoxicity due to antituberculosis therapy. Clinical profile and reintroduction of therapy. J Clin Gastroenterol 1996;22(3):211-4.            

CrossRef | Google Scholar | PubMed
23

Dossing M, Wilcke JT, Askgaard DS, et al. Liver injury during antituberculosis treatment: an 11-year study. Tuber Lung Dis 1996;77(4):335-40.  

CrossRef | Google Scholar | PubMed
24

Gulati K, Ray A, Vijayan VK. Assessment of protective role of polyherbal preparation, Livina, against anti-tubercular drug induced liver dysfunction. Indian J Exp Biol 2010;48(3):318-22.         

Google Scholar | PubMed
25

Vijayalakshmi A, Thanmayi G, Jayakumari S. A prospective study on abnormal liver function test patterns in patients receiving anti-tuberculosis therapy. Asian J Pharm Clin Res 2016;9(5):136-9.         

Google Scholar |
26

Sharma SK, Singla R, Sarda P, et al. Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity. Clin Infect Dis. 2010;50(6):833-9.            

CrossRef | Google Scholar | PubMed
27

Girling DJ. The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamide. Tubercle 1978;59(1):13-32.          

CrossRef | Google Scholar | PubMed
28

Ormerod LP, Horsfield N. Frequency and type of reactions to antituberculosis drugs: observations in routine treatment. Tuber Lung Dis 1996;77(1):37-42.                      

CrossRef | Google Scholar | PubMed
29

Sharifzadeh M, Rasoulinejad M, Valipour F, et al. Evaluation of patient-related factors associated with causality, preventability, predictability and severity of hepatotoxicity during antituberculosis [correction of antituberclosis] treatment. Pharmacol Res 2005;51(4):353-8.                    

CrossRef | Google Scholar | PubMed
30

Fountain FF, Tolley E, Chrisman CR, et al. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic. Chest 2005;128(1):116-23.             

CrossRef | Google Scholar | PubMed